Payment overview · 2025
General Payments
$48.93
3 reported records · 2 companies
Healthcare provider profile · identity verified
David Barber, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PHOENIX, NY · NPI 1396800454
Verified facts
What the public records show
CMS Open Payments records show David Barber, MD received $48.93 in general payments during 2025 across 3 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 58.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $28.36 | 58.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.57 | 42.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $48.93 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $28.36 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 517 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 480 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 459 | 111 |
| Lisinopril | Lisinopril | 380 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 360 | 70 |
| Omeprazole | Omeprazole | 327 | 80 |
| Metformin Hcl | Metformin Hcl | 303 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 53 |
| Gabapentin | Gabapentin | 254 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 56 |
| Losartan Potassium | Losartan Potassium | 212 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 193 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 53 |
| Tramadol Hcl | Tramadol Hcl | 171 | 38 |
| Alprazolam | Alprazolam | 170 | 31 |
| Prednisone | Prednisone | 155 | 56 |
| Fluoxetine Hcl | Fluoxetine Hcl | 149 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 29 |
| Alendronate Sodium | Alendronate Sodium | 146 | 28 |
| Simvastatin | Simvastatin | 144 | 41 |
| Trulicity | Dulaglutide | 135 | 15 |
| Potassium Chloride | Potassium Chloride | 132 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 34 |
| Montelukast Sodium | Montelukast Sodium | 119 | 29 |
| Pregabalin | Pregabalin | 119 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 31 |
| Famotidine | Famotidine | 106 | 17 |
| Xarelto | Rivaroxaban | 105 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 100 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 21 |
| Torsemide | Torsemide | 89 | 24 |
| Spironolactone | Spironolactone | 86 | 20 |
| Glimepiride | Glimepiride | 84 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 21 |
| Irbesartan | Irbesartan | 81 | 14 |
| Atenolol | Atenolol | 79 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 19 |
| Glipizide Er | Glipizide | 76 | 16 |
| Carvedilol | Carvedilol | 74 | 18 |
| Ozempic | Semaglutide | 74 | 13 |
| Sertraline Hcl | Sertraline Hcl | 74 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 15 |
| Meloxicam | Meloxicam | 71 | 18 |
| Terazosin Hcl | Terazosin Hcl | 68 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | suppressed |
| Allopurinol | Allopurinol | 65 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 65 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 17 |
| Ezetimibe | Ezetimibe | 63 | 16 |
| Jardiance | Empagliflozin | 59 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 57 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 54 | 13 |
| Glipizide | Glipizide | 53 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 19 |
| Eliquis | Apixaban | 52 | 12 |
| Furosemide | Furosemide | 51 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 45 | 45 |
| Metformin Hcl Er | Metformin Hcl | 45 | 14 |
| Chlorthalidone | Chlorthalidone | 44 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 11 |
| Topiramate | Topiramate | 41 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 38 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 25 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 21 |
| Hydrocortisone | Hydrocortisone | 30 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 11 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 20 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 20 | 20 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Wegovy | Semaglutide | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Klor-Con M10 | Potassium Chloride | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 14 |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $48.93 · 3 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | Ozempic, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error